CDK inhibitors in clinical development for the treatment of cancer

Author： Fischer Peter M Gianella-Borradori Athos

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.6, 2003-06, pp. : 955-970

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Akt inhibitors in clinical development for the treatment of cancer

By Pal Sumanta Kumar Reckamp Karen Yu Hua Figlin Robert A

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1355-1366

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents

Current Medicinal Chemistry, Vol. 22, Iss. 2, 2014-12 ,pp. : 237-263

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Current Medicinal Chemistry, Vol. 20, Iss. 20, 2013-07 ,pp. : 2537-2551

Bentham Science Publishers

Access to resources Recommend Favorite

CDK Inhibitors: From the Bench to Clinical Trials

Current Drug Targets, Vol. 11, Iss. 3, 2010-03 ,pp. : 279-290

Bentham Science Publishers

Access to resources Recommend Favorite

ATP-noncompetitive CDK inhibitors for cancer therapy: an overview

By Abate Agnese Anna

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 7, 2013-11 ,pp. : 895-906

Informa Healthcare

Access to resources Recommend Favorite